Antimicrobial Agents Practice Questions

Q: What is the drug of choice for treating Mycoplasma infections?

Azithromycin. ***Azithromycin*** - **Azithromycin** is a macrolide antibiotic, which is highly effective against **Mycoplasma species** due to its mechanism of inhibiting bacterial protein synthesis. - **Mycoplasma** lacks a cell wall, rendering beta-lactam antibiotics ineffective; macrolides like azithromycin are therefore a primary choice. *Cefadroxil* - **Cefadroxil** is a **cephalosporin antibiotic** (a type of beta-lactam), which targets bacterial cell wall synthesis. - **Mycoplasma** species intrinsically lack a cell wall, making them resistant to all beta-lactam antibiotics, including cefadroxil. *Erythromycin* - **Erythromycin** is an older macrolide antibiotic that, while effective against Mycoplasma, has a **less favorable pharmacokinetic profile** (e.g., more frequent dosing) and often more gastrointestinal side effects compared to newer macrolides like azithromycin. - **Azithromycin** is generally preferred due to its **once-daily dosing** and better tolerability, making it the more common "drug of choice" among macrolides for Mycoplasma infections. *Chloramphenicol* - **Chloramphenicol** is a broad-spectrum antibiotic that inhibits bacterial protein synthesis, but it is typically reserved for **life-threatening infections** due to its potential for serious side effects, such as **bone marrow suppression** (aplastic anemia). - While active against Mycoplasma, its toxicity profile makes it **not a first-line drug of choice** when safer and equally effective alternatives like macrolides are available.

Q: Which of the following bacteria are not affected by streptogramins?

E. coli. ***E. coli*** - Streptogramins (e.g., quinupristin/dalfopristin) are primarily active against **Gram-positive bacteria**. - ***E. coli*** is a **Gram-negative bacterium** with intrinsic resistance to streptogramins due to poor penetration through the outer membrane. - This makes E. coli the most clearly **NOT affected** by streptogramins among the options. *Staphylococcus aureus* - **Streptogramins** are highly effective against **Gram-positive bacteria**, including **Staphylococcus aureus**. - They are particularly useful for treating **multidrug-resistant strains like MRSA** and vancomycin-resistant Enterococcus faecium. - This is one of their primary clinical indications. *Legionella* - **_Legionella_** species are **atypical intracellular bacteria** that cause Legionnaires' disease. - While streptogramins have some intracellular penetration, they have **limited and unreliable activity** against Legionella. - Standard treatment uses macrolides or fluoroquinolones, NOT streptogramins. *M. pneumoniae* - **_Mycoplasma pneumoniae_** is an **atypical bacterium** lacking a cell wall that causes atypical pneumonia. - Streptogramins have **limited clinical activity** against M. pneumoniae and are NOT used as standard therapy. - Preferred treatments include macrolides, tetracyclines, or fluoroquinolones.

Q: Which antibiotic acts by inhibiting protein synthesis?

Doxycycline. ***Doxycycline*** - **Doxycycline** is a **tetracycline antibiotic** that inhibits bacterial protein synthesis by binding reversibly to the **30S ribosomal subunit**, preventing the attachment of aminoacyl-tRNA. - This action effectively blocks the elongation of the peptide chain, halting bacterial growth. *Cefotetan* - **Cefotetan** is a **second-generation cephalosporin** that inhibits bacterial cell wall synthesis. - It does this by binding to and inactivating **penicillin-binding proteins (PBPs)**, which are essential for peptidoglycan cross-linking. *Ciprofloxacin* - **Ciprofloxacin** is a **fluoroquinolone antibiotic** that inhibits bacterial **DNA synthesis**. - It targets **DNA gyrase (topoisomerase II)** and **topoisomerase IV**, enzymes crucial for DNA replication, transcription, and repair. *Oxacillin* - **Oxacillin** is a **beta-lactam antibiotic** (specifically a penicillinase-resistant penicillin) that, like cephalosporins, inhibits bacterial **cell wall synthesis**. - It achieves this by binding to and inactivating **penicillin-binding proteins (PBPs)**, thereby interfering with peptidoglycan cross-linking.

Q: Which of the following drugs causes flaccid paralysis of ascaris?

Piperazine. ***Piperazine*** - Piperazine acts as a **GABA agonist**, leading to **hyperpolarization** of the *Ascaris* muscle cells. - This hyperpolarization causes muscular paralysis, making the worms unable to maintain their position and thus they are expelled. *Albendazole* - Albendazole primarily works by inhibiting **microtubule polymerization** in the parasitic worms, which impairs glucose uptake and energy metabolism. - This leads to the **slow death** of the worms, rather than acute flaccid paralysis. *Pyrantel pamoate* - Pyrantel pamoate induces a **nicotinic acetylcholine receptor agonism** in nematodes, causing **spastic paralysis** [1]. - The worms become irreversibly paralyzed in a contracted state, unlike the flaccid paralysis caused by piperazine. *Ivermectin* - Ivermectin works by binding to **glutamate-gated chloride channels** in invertebrate nerve and muscle cells. - This binding leads to an increase in chloride ion permeability and **hyperpolarization** of the neuronal membrane, causing paralysis and eventual death of the parasite.

Q: Which of the following drugs is not effective against methicillin-resistant Staphylococcus aureus (MRSA)?

Cefaclor. ***Cefaclor*** - **Cefaclor** is a second-generation cephalosporin, and like most beta-lactam antibiotics, it is **ineffective against MRSA** due to the presence of the **mecA gene** which codes for an altered penicillin-binding protein (PBP2a). - MRSA's resistance mechanism renders beta-lactams, including cefaclor, unable to bind effectively to their target, thus inhibiting their antibacterial action. *Cotrimoxazole* - **Cotrimoxazole** (trimethoprim-sulfamethoxazole) is often effective against MRSA, especially for **skin and soft tissue infections**, making it a common choice for outpatient treatment. - It works by inhibiting two consecutive steps in the bacterial **folic acid synthesis pathway**, preventing nucleic acid and protein synthesis. *Ciprofloxacin* - **Ciprofloxacin**, a fluoroquinolone, can be effective against certain strains of MRSA, although **resistance rates have increased**, limiting its broad utility. - Its mechanism involves inhibiting **bacterial DNA gyrase** and topoisomerase IV, essential enzymes for DNA replication. *Vancomycin* - **Vancomycin** is a cornerstone in the treatment of **severe MRSA infections**, particularly in intravenous formulations for systemic infections. - It inhibits **bacterial cell wall synthesis** by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors.

Q: All the following statements are true regarding beta-lactams except:

Aztreonam shows cross-reactivity with cephalexin.. ***Aztreonam shows cross-reactivity with cephalexin.*** - **Aztreonam** is a monobactam with a distinct chemical structure from other beta-lactams, resulting in a different **allergy profile** and lack of significant **cross-reactivity** with other beta-lactams, including cephalosporins like cephalexin. - Its unique structure also means it is specifically active against **gram-negative bacteria** and generally resistant to common beta-lactamases that deactivate other beta-lactams. *Imipenem should be given with cilastatin* - **Imipenem** is rapidly metabolized in the renal tubules by **dehydropeptidase-1**, leading to reduced antibiotic concentrations and potential for nephrotoxicity. - **Cilastatin** is a dehydropeptidase inhibitor that prevents the breakdown of imipenem, ensuring adequate drug levels and reducing renal damage. *Methicillin is not orally bioavailable and is given parenterally.* - **Methicillin** is an acid-labile penicillin, meaning it is extensively degraded by stomach acid when taken orally, leading to poor absorption. - Due to its instability in acidic environments, methicillin must be administered **parenterally (intravenously or intramuscularly)** to achieve therapeutic concentrations. *Meropenem does not require cilastatin for protection against renal toxicity.* - **Meropenem** is another carbapenem, but it is much more stable to metabolism by **renal dehydropeptidase-1** compared to imipenem. - This inherent stability eliminates the need for co-administration with **cilastatin** to prevent its degradation and protect against nephrotoxicity.

Q: All of the following are risk factors for renal toxicity caused by aminoglycosides EXCEPT:

Simultaneous use of penicillin. ***Simultaneous use of penicillin*** - Penicillins are **not considered a major risk factor** for aminoglycoside nephrotoxicity. - While aminoglycosides and penicillins can be inactivated when mixed **in vitro** (in IV solutions), this does not translate to a protective effect against renal toxicity **in vivo**. - The major nephrotoxic drug combinations with aminoglycosides include **vancomycin, amphotericin B, cyclosporine, NSAIDs, and loop diuretics** - not penicillins. *Hypokalemia* - **Electrolyte imbalances**, such as hypokalemia, can worsen renal function and increase the susceptibility of the kidneys to damage from nephrotoxic drugs like aminoglycosides. - **Volume depletion** and electrolyte disturbances are common comorbidities that exacerbate aminoglycoside-induced acute kidney injury. *Aminoglycoside administration in recent past* - Prior exposure to aminoglycosides, especially within a short period, can lead to **cumulative toxicity** due to incomplete renal recovery from previous dosing. - The kidneys require time to regenerate epithelial cells damaged by aminoglycosides, and repeated exposure increases the risk of **irreversible damage**. *Elderly patient* - **Age** is a significant risk factor because elderly patients often have **decreased renal blood flow** and a reduced number of functional nephrons. - The **glomerular filtration rate (GFR)** naturally declines with age, making the kidneys more vulnerable to drug-induced injury.

Q: What is the treatment of choice for Campylobacter infections?

Erythromycin. Erythromycin - **Erythromycin**, a macrolide antibiotic, is the **correct answer among the given options** for *Campylobacter* infections. - It works by inhibiting bacterial protein synthesis at the 50S ribosomal subunit, effectively reducing the duration and severity of symptoms in acute gastroenteritis. - **Modern practice note:** While azithromycin (another macrolide) has largely replaced erythromycin as the **preferred first-line agent** due to better tolerability, once-daily dosing, and fewer GI side effects, erythromycin remains effective and is the best choice listed here [1]. - Macrolides are particularly indicated in severe cases with high fever, bloody diarrhea, or in immunocompromised patients. *Tetracycline* - While tetracyclines have broad-spectrum activity, they are **not first-line treatment** for *Campylobacter* due to increasing resistance rates globally [2]. - Resistance mechanisms include efflux pumps and ribosomal protection proteins. - May still have some role in regions with documented susceptibility, but macrolides are preferred. *Ampicillin* - **Ampicillin** and other beta-lactam antibiotics are **ineffective** against *Campylobacter* species. - *Campylobacter* possesses intrinsic resistance to beta-lactams through beta-lactamase production and altered penicillin-binding proteins. - Cell wall synthesis inhibitors are therefore not useful for this infection. *Ciprofloxacin* - **Ciprofloxacin** and other fluoroquinolones were previously common first-line agents but are **no longer recommended** due to widespread resistance. - Resistance rates exceed 50-90% in many countries, particularly linked to fluoroquinolone use in poultry farming. - Should only be used if susceptibility testing confirms sensitivity, which is rarely practical in acute gastroenteritis.

Q: Drug of choice for rheumatic fever prophylaxis in a penicillin-allergic patient is?

Erythromycin. ***Erythromycin*** - **Erythromycin** is the **recommended alternative** for **rheumatic fever prophylaxis** in patients with **penicillin allergy** according to **American Heart Association (AHA) guidelines**. - Typical regimen: **Erythromycin estolate 250 mg BID** or **erythromycin ethylsuccinate 400 mg BID**. - Effective against **Streptococcus pyogenes** (Group A Streptococcus), the causative organism of acute rheumatic fever. - While macrolide resistance exists in some regions, erythromycin remains the **guideline-recommended choice** when penicillin cannot be used. *Clindamycin* - **Clindamycin** is **not recommended** by major guidelines (AHA, WHO) for routine rheumatic fever prophylaxis. - Lacks adequate evidence and official guideline support for this specific indication. - May be considered in specific cases but is not the standard alternative. *Vancomycin* - **Vancomycin** is reserved for **multidrug-resistant infections** such as **MRSA**. - Not indicated for rheumatic fever prophylaxis due to high cost, need for IV administration, and potential for resistance development. - Reserved for life-threatening infections where other options have failed. *Gentamycin* - **Gentamycin** is an **aminoglycoside** used primarily for **severe gram-negative infections**. - Lacks adequate activity against **Streptococcus pyogenes**. - Not appropriate for rheumatic fever prophylaxis.

Question 1

What is the drug of choice for treating Mycoplasma infections?

Accepted Answer

Azithromycin

Answer

Cefadroxil

Answer

Erythromycin

Answer

Chloramphenicol

Question 2

Which of the following bacteria are not affected by streptogramins?

Accepted Answer

E. coli

Answer

Legionella

Answer

Staphylococcus aureus

Answer

M. pneumoniae

Question 3

Which antibiotic acts by inhibiting protein synthesis?

Accepted Answer

Doxycycline

Answer

Cefotetan

Answer

Ciprofloxacin

Answer

Oxacillin

Question 4

Which of the following drugs causes flaccid paralysis of ascaris?

Accepted Answer

Piperazine

Answer

Ivermectin

Answer

Albendazole

Answer

Pyrantel pamoate

Question 5

Which of the following drugs is not effective against methicillin-resistant Staphylococcus aureus (MRSA)?

Accepted Answer

Cefaclor

Answer

Ciprofloxacin

Answer

Cotrimoxazole

Answer

Vancomycin

Question 6

All the following statements are true regarding beta-lactams except:

Accepted Answer

Aztreonam shows cross-reactivity with cephalexin.

Answer

Methicillin is not orally bioavailable and is given parenterally.

Answer

Imipenem should be given with cilastatin

Answer

Meropenem does not require cilastatin for protection against renal toxicity.

Question 7

All of the following are risk factors for renal toxicity caused by aminoglycosides EXCEPT:

Accepted Answer

Simultaneous use of penicillin

Answer

Hypokalemia

Answer

Aminoglycoside administration in recent past

Answer

Elderly patient

Question 8

All of the following are true about rifabutin except which of the following?

Accepted Answer

It is more effective for newly diagnosed TB as compared to Rifampicin

Answer

It has lesser incidence of drug interactions as compared to Rifampicin

Answer

It is more effective against MAC as compared to Rifampicin

Answer

It has longer half life than Rifampicin

Question 9

What is the treatment of choice for Campylobacter infections?

Accepted Answer

Erythromycin

Answer

Tetracycline

Answer

Ampicillin

Answer

Ciprofloxacin

Question 10

Drug of choice for rheumatic fever prophylaxis in a penicillin-allergic patient is?

Accepted Answer

Erythromycin

Answer

Vancomycin

Answer

Gentamycin

Answer

Clindamycin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?